Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2017

Planlagt Fastgjort Låst Flyttet Genmab
1.9k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #1127

    show starting again,

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #1128

      🙂

      1 Reply Last reply
      0
      • J Offline
        J Offline
        jkj
        wrote on sidst redigeret af
        #1129

        Denne store analyse siger 1,8 mia for dara i usa i 2020http://info.evaluategroup.com/rs/607-YGS-364/images/wp16.pdf

        1 Reply Last reply
        0
        • G Offline
          G Offline
          GlobalMacro 0
          wrote on sidst redigeret af
          #1130

          I think it was during the part where they were explaining their vision relating prevention of disease > smoldring MM

          1 Reply Last reply
          0
          • G Offline
            G Offline
            GlobalMacro 0
            wrote on sidst redigeret af
            #1131

            From live presentation on oncology studies : "move phase 1 studies quick trough registration"!!

            1 Reply Last reply
            0
            • Legolas23L Offline
              Legolas23L Offline
              Legolas23
              wrote on sidst redigeret af
              #1132

              Maybe it comes as late breaking at ASCO

              1 Reply Last reply
              0
              • J Offline
                J Offline
                JKY_VH
                wrote on sidst redigeret af
                #1133

                https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=318483007&sourcecode=omxnews

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  jkj
                  wrote on sidst redigeret af
                  #1134

                  Konsensus 4.9 mia 2022 side 44http://info.evaluategroup.com/rs/607-YGS-364/images/wp16.pdf

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #1135

                    Or EHA just after ASCO - last year Castor at ASCO and Pollux at EHA

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1136

                      did Lebowitz just say he thinks SubQ could be administered in 5 minutes? Much f
                      aster as i heard before

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #1137

                        Angående konsensus på 2,8 milliarder dollars, så hvis man leger med tanken om Nordea og to andre analytikere, så skal de i gennemsnit ligge på 1,5 milliard - 5,4+1,5+1,5=8,4 og dermed 2,8 i gennemsnit. De 1,5 milliard når vi måske allerede i år. Nordea ligger bestemt i den høje ende, men 2,8 milliard er langt fra sandheden, hvilket bevidner at der må være en del analyser der ikke er opdateret

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #1138

                          Jan all so said 5 minutes in the last CC

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #1139

                            Sleeping analyst they are.

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              saltpeter
                              wrote on sidst redigeret af
                              #1140

                              3 new Phase III studies of daratumumab planned in multiple myeloma and amyloidosis
                              Studies planned to start between second half 2017 and first quarter 2018
                              Copenhagen, Denmark; May 17, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its partner Janssen Biotech, Inc. plans to start four new studies of daratumumab in multiple myeloma and amyloidosis. The studies described below are currently planned to start between the second half of 2017 and the first quarter of 2018 and may be

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                saltpeter
                                wrote on sidst redigeret af
                                #1141

                                subject to change. DARZALEX is being developed under an August 2012 agreement in which Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize the product.

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  saltpeter
                                  wrote on sidst redigeret af
                                  #1142

                                  Phase III study of daratumumab in smoldering multiple myeloma
                                  Phase III study comparing the subcutaneous and intravenous administration of daratumumab in relapsed and refractory multiple myeloma
                                  Phase III study of daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone for amyloidosis
                                  Phase II study of subcutaneous daratumumab in combination with standard of care regimens for frontline and relapsed multiple myeloma

                                  1 Reply Last reply
                                  0
                                  • StockBullS Offline
                                    StockBullS Offline
                                    StockBull
                                    wrote on sidst redigeret af
                                    #1143

                                    Hvis gennemsnit er 2.8 og Nordea har 5.3 saa virker Nordeas kurstarget lavt i forhold til dem som ligger under 5.3

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JohnW
                                      wrote on sidst redigeret af
                                      #1144

                                      @StockBull, den forstår jeg altså ikke. Kan du uddybe?

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JohnW
                                        wrote on sidst redigeret af
                                        #1145

                                        @StockBull, sorry, nu fik jeg den. Du skrev kurstarget. Jeg læste det som salgstarget. My bad.

                                        1 Reply Last reply
                                        0
                                        • StockBullS Offline
                                          StockBullS Offline
                                          StockBull
                                          wrote on sidst redigeret af
                                          #1146

                                          Gennemsnits kurstarget er 1475 og hvis du sammenligner det med gennemsnits salg 2.8B usd saa virker nordeas kurstarget paa 1570 lavt i forhold til deres salg paa 5.3

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger